Your browser doesn't support javascript.
loading
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
Tap, William D; Papai, Zsuzsanna; Van Tine, Brian A; Attia, Steven; Ganjoo, Kristen N; Jones, Robin L; Schuetze, Scott; Reed, Damon; Chawla, Sant P; Riedel, Richard F; Krarup-Hansen, Anders; Toulmonde, Maud; Ray-Coquard, Isabelle; Hohenberger, Peter; Grignani, Giovanni; Cranmer, Lee D; Okuno, Scott; Agulnik, Mark; Read, William; Ryan, Christopher W; Alcindor, Thierry; Del Muro, Xavier F Garcia; Budd, G Thomas; Tawbi, Hussein; Pearce, Tillman; Kroll, Stew; Reinke, Denise K; Schöffski, Patrick.
Afiliação
  • Tap WD; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: tapw@mskcc.org.
  • Papai Z; Allami Egeszsegugyi Kozpont (State Health Center), Budapest, Hungary.
  • Van Tine BA; Washington University School of Medicine, St Louis, MO, USA.
  • Attia S; Mayo Clinic Florida, Jacksonville, FL, USA.
  • Ganjoo KN; Stanford University Department of Medicine Division of Oncology, Stanford, CA, USA.
  • Jones RL; University of Washington Cancer Center/Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Schuetze S; University of Michigan Cancer Center, Ann Arbor, MI, USA.
  • Reed D; Moffitt Cancer Center, Tampa, FL, USA.
  • Chawla SP; Sarcoma Oncology Center, Santa Monica, CA, USA.
  • Riedel RF; Duke University Medical Center, Durham, NC, USA.
  • Krarup-Hansen A; Herlev Hospital, Herlev, Denmark.
  • Toulmonde M; Institut Bergonié, Bordeaux, France.
  • Ray-Coquard I; Centre Léon Bérard, Lyon, France.
  • Hohenberger P; Universitätsklinikum Mannheim, Mannheim, Germany.
  • Grignani G; Candiolo Cancer Institute, FPO, IRCCS, Turin, Italy.
  • Cranmer LD; University of Arizona Cancer Center, Seattle, WA, USA.
  • Okuno S; Mayo Clinic, Rochester, MN, USA.
  • Agulnik M; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
  • Read W; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Ryan CW; Oregon Health and Science University, Portland, OR, USA.
  • Alcindor T; Department of Oncology, McGill University, Montreal, QC, Canada.
  • Del Muro XFG; ICO Hospital Duran i Reynals, Barcelona, Spain.
  • Budd GT; Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Tawbi H; University of Pittsburgh Medical Center, Houston, TX, USA.
  • Pearce T; Threshold Pharmaceuticals, South San Francisco, CA, USA.
  • Kroll S; Threshold Pharmaceuticals, South San Francisco, CA, USA.
  • Reinke DK; Sarcoma Alliance for Research through Collaboration, Ann Arbor, MI, USA.
  • Schöffski P; UZ Leuven, Campus Gasthuisberg, Leuven, Belgium.
Lancet Oncol ; 18(8): 1089-1103, 2017 08.
Article em En | MEDLINE | ID: mdl-28651927
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma / Neoplasias de Tecidos Moles / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Antibióticos Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma / Neoplasias de Tecidos Moles / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Antibióticos Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article